// App-Quantinova.ai

9583 : Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.

Researchers

Presenter

  • Robyn Saw

Principal Investigators

  • Alexander M. Menzies

  • Alexander Guminski

  • Omgo E Nieweg

  • Kerwin F. Shannon

  • Maria Gonzalez

  • Sydney Ch'ng

  • Richard Kefford

  • John F Thompson

  • Jonathan Stretch

  • Andrew J Spillane

  • Richard A Scolyer

  • Georgina V. Long

Medical Centers

  • Melanoma Institute Australia and The University of Sydney, North Sydney, Australia

  • Melanoma Institute Australia, Royal North Shore Hospital, The University of Sydney, North Sydney, Australia

  • Melanoma Institute Australia, North Sydney, Australia

  • The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands

  • Melanoma Institute Australia, North Sydney, Australia

  • Melanoma Institute Australia, North Sydney, Australia

  • Institute of Academic Surgery, Royal Prince Alfred Hospital, Camperdown, Australia

  • Crown Princess Mary Cancer Centre Westmead, Sydney, Australia

  • Melanoma Institute Australia, Royal North Shore Hospital, The University of Sydney, North Sydney, Australia

  • The University of Sydney, North Sydney, Australia

  • Royal Prince Alfred Hospital/Melanoma Institute Australia/University of Sydney, Sydney, Australia

Locations

  • Australia

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Dabrafenib Mesylate

  • Trametinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01972347

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved